Table 3. Response to Treatment With Tucatinib Combined With Trastuzumab and Capecitabine (TTC) According to RECIST, Version 1.1, Criteria per Local Investigatora.
| RECIST criteria response | Tumor response | Brain tumor response in patients with active brain metastases prior to TTC initiation (n = 16) | ||
|---|---|---|---|---|
| Overall population (n = 101) | Progression during trastuzumab-deruxtecan treatment (n = 82) | Stopped trastuzumab-deruxtecan treatment for toxic effects (n = 18) | ||
| Complete response | 2/89 (2.2) | 0/72 | 2/16 (12.5) | 1/15 (6.7) |
| Partial response | 27/89 (30.3) | 23/72 (31.9) | 4/16 (25.0) | 2/15 (13.3) |
| Stable disease | 28/89 (31.5) | 22/72 (30.6) | 6/16 (37.5) | 7/15 (46.7) |
| Progressive disease | 32/89 (36.0) | 27/72 (37.5) | 4/16 (25.0) | 5/15 (33.3) |
| No. not available | 12 | 10 | 2 | 1 |
| Overall response rate | 29/89 (32.6) | 23/72 (31.9) | 6/16 (37.5) | 3/15 (20.0) |
| Disease control rate | 57/89 (64.0) | 45/72 (62.5) | 12/16 (75.0) | 10/15 (66.7) |
Abbreviation: RECIST, Response Evaluation Criteria in Solid Tumors.
a
Unless otherwise indicated, data are expressed as No./total No. (%) of patients with data available.